Kenneth Mcgrath Acquires 32,300 Shares of OraSure Technologies (NASDAQ:OSUR) Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth Mcgrath purchased 32,300 shares of OraSure Technologies stock in a transaction on Friday, March 20th. The stock was bought at an average price of $2.93 per share, for a total transaction of $94,639.00. Following the transaction, the chief financial officer directly owned 589,562 shares in the company, valued at approximately $1,727,416.66. The trade was a 5.80% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

OraSure Technologies Price Performance

Shares of OSUR opened at $3.06 on Wednesday. The business has a 50-day moving average of $2.87 and a 200-day moving average of $2.78. The company has a market capitalization of $211.54 million, a price-to-earnings ratio of -3.29 and a beta of 0.88. OraSure Technologies, Inc. has a 1 year low of $2.08 and a 1 year high of $3.82.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The company had revenue of $26.76 million during the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%. As a group, sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.08 EPS for the current year.

Institutional Investors Weigh In On OraSure Technologies

Several large investors have recently added to or reduced their stakes in the business. Amundi acquired a new position in OraSure Technologies in the first quarter valued at approximately $47,000. AQR Capital Management LLC grew its position in shares of OraSure Technologies by 48.3% during the 1st quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock worth $3,511,000 after buying an additional 339,493 shares during the period. NewEdge Advisors LLC increased its stake in shares of OraSure Technologies by 32,595.9% in the 1st quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock valued at $161,000 after acquiring an additional 47,590 shares in the last quarter. Empowered Funds LLC increased its stake in shares of OraSure Technologies by 7.2% in the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock valued at $1,366,000 after acquiring an additional 27,310 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of OraSure Technologies by 32.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 8,133 shares during the period. Institutional investors and hedge funds own 93.50% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of OraSure Technologies in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, OraSure Technologies presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.